Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 5/20 | 0.43 |
| ▸ | MMP13 | P45452 | 5/20 | 0.43 |
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | MMP9 | P14780 | 5/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 4/20 | 0.43 |
| ▸ | MMP7 | P09237 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634460 | 1.00 | MEN1 (0.47) | MEN1LMNAKMT2ATAS2R14PTGES | |
| SCHEMBL3635250 | 0.90 | LMNA (0.51) | MEN1LMNAKMT2ATAS2R14PTGES | |
| SCHEMBL3746742 | 0.89 | HPGD (0.41) | MEN1KMT2A | |
| SCHEMBL3634404 | 0.89 | HPGD (0.41) | MEN1KMT2A | |
| SCHEMBL3632109 | 0.85 | TSHR (0.46) | LMNATAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL3636191 | 0.83 | LMNA (0.42) | MEN1LMNAKMT2ATSHRMAPK1 | |
| SCHEMBL3750658 | 0.83 | HTR2A (0.39) | MMP8MMP13MMP1MMP2MMP3 | |
| SCHEMBL3639167 | 0.83 | HTR2A (0.39) | MMP8MMP13MMP1MMP2MMP3 | |
| SCHEMBL3631393 | 0.81 | MMP8 (0.42) | MEN1LMNAKMT2APTGESMMP8 | |
| SCHEMBL3631395 | 0.81 | MMP8 (0.42) | MEN1LMNAKMT2APTGESMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | claimed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| EP-2155676-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | Commissariat à l'Energie Atomique (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008146172-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | MEN1 2707/4885LMNA 3040/4885KMT2A 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.